Strong H1 results saw contribuons from marketed products Cresemba and Zevtera grow 17% YoY to CHF62.0m with management confirming 2020E revenue guidance between CHF128m - CHF138m. We highlight the connued growth of cash generang, non deferred revenuesfrom these products(CHF36.5m,+21% YoY), which more closely reflect the underlying in market performance and are increasingly responsible for greater proporon of total revenue. We maintain and reiterate our OUTPERFORM recommendaon, as the cur
17 Aug 2020
Beating estimates and potential future COVID tailwind
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Beating estimates and potential future COVID tailwind
Basilea Pharmaceutica AG (0QNA:LON) | 4,620 0 0.0% | Mkt Cap: 605.3m
- Published:
17 Aug 2020 - Author:
-
Pages:
14
Strong H1 results saw contribuons from marketed products Cresemba and Zevtera grow 17% YoY to CHF62.0m with management confirming 2020E revenue guidance between CHF128m - CHF138m. We highlight the connued growth of cash generang, non deferred revenuesfrom these products(CHF36.5m,+21% YoY), which more closely reflect the underlying in market performance and are increasingly responsible for greater proporon of total revenue. We maintain and reiterate our OUTPERFORM recommendaon, as the cur